In the October 2008 issue of Cardiology Review, we incorrectly stated in our Product Spotlight section that “Boston Scientific received approval in July 2008 for their Xience™ V Everolimus- Eluting Coronary Stent for the treatment of coronary artery disease.” It should have said that Abbott Vascular received this approval and will market the Xience V. Abbott supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS™ Everolimus-Eluting Coronary Stent System. We regret the mistake.